Derrick Sung, the Chief Financial Officer, has resigned from the role of CFO at Pulmonx Corporation to pursue another opportunity. John McKune, Vice President and Corporate Controller, has been appointed as the Interim Chief Financial Officer. Dr. Sung will remain with the company until October 31, 2023, to ensure a smooth transition.
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has provided preliminary, unaudited revenue figures for the third quarter of 2023, estimating it to be approximately $17.6 million, representing a growth of about 30% compared to the same quarter last year.
Pulmonx will host a conference call on October 30, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third-quarter financial results and full-year outlook.
Have you read?
Report: Grenada Citizenship by Investment Programme, 2023.
Report: Jordan Citizenship by Investment Programme, 2023.
Report: Malta Citizenship by Investment Programme, 2023.
Report: Saint Lucia Citizenship by Investment Programme, 2023.
Report: St Kitts and Nevis Citizenship by Investment Programme, 2023.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
